New Drug Combination Treats Hepatitis C Patients Also Infected with HIV

Novel treatment has 97 percent success rate in co-infected patients —

Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV. … Read the full story from the UC San Diego News Center


David L. Wyles, MD, is lead author of the New England Journal of Medicine article that reports the results of the multi-center study. Dr. Wyles is associate professor of clinical medicine in the Division of Infectious Diseases.

Read the article online:

Wyles D.L., Ruane P.J., Sulkowski M.S., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine July 21, 2015, 10.1056/NEJMoa1503153.  Free full text

Discovery Provides Blueprint for New Drugs That Can Inhibit Hepatitis C Virus

Finding Could Pave Way for Drugs Against Virus That Kills More In US Than HIV

Chemists at the University of California, San Diego have produced the first high resolution structure of a molecule that when attached to the genetic material of the hepatitis C virus prevents it from reproducing . …. Read the full story from the UCSD Newsroom

Laboratory test tubes
David L. Wyles, MD, is a coauthor of the study report. He is associate professor of clinical medicine in the Division of Infectious Diseases and a researcher in the UC San Diego Antiviral Research Center.

Read the study report in the Proceedings of the National Academy of Sciences

Related story:
UC San Diego School of Medicine Launches Hepatitis C Clinical Trials

UC San Diego School of Medicine Launches Hepatitis C Clinical Trials

A collaborative partnership between the UC San Diego Liver Center and Antiviral Research Center (AVRC) has resulted in 19 clinical trials for hepatitis C virus (HCV), focused on developing more effective and well-tolerated HCV treatments…. Read the full story from the UCSD Newsroom

Department of Medicine clinical trials investigators Alexander Kuo, MD, and David L. Wyles, MD, are featured in this news release.

Dr. Kuo is associate professor of medicine in the Division of Gastroenterology and medical director of the Liver Transplant Program at the UC San Diego Health System Liver Center.

Dr. Wyles, a researcher at the UC San Diego Antiviral Research Center, is associate professor of clinical medicine in the Division of Infectious Diseases.